4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-21-021092
Chief Scientific Officer sold 800 shares at $45.00 ($36,000)
- Chief Scientific Officer acquired 800 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-03-16 | Exercise or conversion : show line 1 in the form | +800 | $7.26 | $5,808 | 14,604 | D |
| 2021-03-16 | Sale : show line 2 in the form | −800 | $45.00 | $36,000 | 13,804 | D |
| Open-market sales · 800 sh · avg $45.00 · $36,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2021-03-16 | Exercise or conversion : show line 3 in the form Employee Stock Option (right to buy) | −800 | $7.26 | 2030-02-26 | 800 | 74,266 | D |
Loading xslF345X03/doc4.xml…